Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Discovery Fund”. A copy of the letter is available to download here. Baron Discovery Fund appreciated by 19.08% (Institutional Shares) in the quarter, underperforming the Russell 2000 Growth Index, which gained 25.71%. This lag was primarily due to a momentum-driven “AI winners” trade, with these stocks largely contributing to the Benchmark’s performance. The Fund experienced a 6.63% underperformance, largely driven by an underweight in strong-performing Momentum and Beta factors. The Fund prioritizes a long-term balanced portfolio over chasing momentum. The letter discussed parallels between the current AI market and the late 1990s dot-com bubble. The firm remains focused on company fundamentals and long-term valuation. Please review the fund’s top five holdings to gain insights into their key selections for 2026.
In its Q2 2026 investor letter, Baron Discovery Fund highlighted Establishment Labs Holdings Inc. (NASDAQ:ESTA). Establishment Labs Holdings Inc. (NASDAQ:ESTA) is a medical device company focused on breast implants and other reconstructive plastic surgeries. On August 11, 2026, Establishment Labs Holdings Inc. (NASDAQ:ESTA) closed at $74.28 per share, reflecting a market capitalization of $2.21 billion. Establishment Labs Holdings Inc. (NASDAQ:ESTA) posted a one‑month return of ‑18.03%, while its shares gained 93.74% over the past 52 weeks.
Baron Discovery Fund stated the following regarding Establishment Labs Holdings Inc. (NASDAQ:ESTA) in its Q2 2026 investor letter:
“Establishment Labs Holdings Inc. (NASDAQ:ESTA) sells next-generation Motiva breast implants that have meaningfully lower safety risks and aesthetic benefits compared to competitors. Shares outperformed in the second quarter, driven by continued strong adoption of Motiva in the U.S. breast augmentation market and anticipation of the upcoming launch in the U.S. breast reconstruction market. Additionally, the macro consumer spending anxieties and silicone supplier contract fears that weighed on the stock last quarter have notably eased. Positive momentum was further amplified by the company’s official inclusion in the Russell 2000 Index, which drives increased institutional visibility and index-related buying. This caused significant upward share price movement, and we trimmed our investment based upon shares nearing our long term valuation targets. We believe Establishment Labs will capture substantial plurality share in the U.S. over the next few years, which is meaningfully reflected in the shares. There is further upside if Establishment Labs is successful in launching its new minimally invasive products which promise easier procedures and faster healing times for its patients.”
Establishment Labs Holdings Inc. (NASDAQ:ESTA) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 36 hedge fund portfolios held Establishment Labs Holdings Inc. (NASDAQ:ESTA) at the end of the first quarter, compared to 39 in the previous quarter. While we acknowledge the risk and potential of Establishment Labs Holdings Inc. (NASDAQ:ESTA) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Establishment Labs Holdings Inc. (NASDAQ:ESTA) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
